The discovery of biomarkers such as phospho-tau217 marked an important advancement in Alzheimer’s diagnosis. This particular ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

Learn about the impact of Alzheimer's family history on brain resilience and memory function. Your family tree may shape your ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the ...

Amyloid and tau can be measured in the cerebrospinal fluid via lumbar puncture or detected using a PET scan. “Brazil lags behind in adopting tests such as amyloid PET scan, which is not widely ...

W ith two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the memory-robbing condition. But tests to detect the condition still lag behind.

Could you describe the profile of a patient who would be a candidate for treatment with amyloid-targeting therapy?

Detection is currently tricky. Brain scans like PET can pick up amyloid plaques, the clumps of protein that are the hallmark of the disease, but by the time these form, people’s brain function ...

CEOi, which lists Biogen, Eisai and Lilly among its members, sees blood-based biomarker testing as more scalable than the amyloid PET scans and CSF tests currently used to confirm an Alzheimer’s ...

they were able to remove more amyloid from the brain. But other biomarker data is less clear. PET imaging scans, for example, didn’t show much of a difference in the amounts of tau protein in ...